Advertiser Disclosure: BestMedsHub may earn a commission when readers sign up with telehealth providers linked on this page. Editorial recommendations are independent. This article is informational only and is not a substitute for personalized care from a licensed clinician.
Last updated: May 20, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~8 min read
Key Takeaways
- Shortage officially over: FDA removed semaglutide from the drug shortage list on Feb 21 2025. Tirzepatide had already been resolved earlier.
- May 2026 stock status: Brand-name Ozempic pens are stocked at most US retail pharmacies. Localized gaps persist for the 2mg pen in high-demand urban zip codes.
- Compounded path narrowed: Mass 503B compounding from the bulks list ended May 22 2025. 503A patient-specific compounding remains legal but is under active FDA review.
- New FDA proposal: Apr 30 2026 — exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Public comments open through Jun 29 2026.
- Ozempic cash pricing 2026: $349/mo via NovoCare self-pay vs $800-$1,100/mo retail.
- Several major compounding labs (ProRx, BPI Labs) ceased GLP-1 production in early 2026 — supply for telehealth providers tightened.
The Ozempic shortage is officially over in May 2026. The FDA removed semaglutide from its drug shortage list on February 21, 2025, and brand-name Ozempic pens are stocked at most US retail pharmacies. Localized stock gaps still occur, particularly for the 2mg pen in high-demand metro areas. Mass compounding ended in 2025; 503A patient-specific compounding remains legal but is under FDA review, with an April 30 2026 proposal that could narrow it further.
Quick Answer: Is There an Ozempic Shortage in May 2026?
No. The FDA delisted semaglutide on Feb 21 2025 and that status holds in May 2026. Brand Ozempic pens (0.25mg, 0.5mg, 1mg, 2mg) are available through normal pharmacy channels — CVS, Walgreens, Walmart, Costco, and independent pharmacies. Novo Nordisk’s US manufacturing footprint scaled materially through 2024-2025 to meet demand. The shortage that defined 2022-2024 is structurally resolved.
The caveats: 2mg pen availability is uneven in dense metro areas (NYC, LA, Miami, DC), and individual pharmacies can run out for 3-7 days between shipments. This is not a national shortage — it’s normal pharmacy-level inventory variance now overlaid on a high-demand drug.
Timeline: 2022 Onset → Feb 21 2025 FDA Delisting → May 2026 Status
| Date | FDA Status | Compounding Allowance | Patient Impact |
|---|---|---|---|
| Mar 2022 | Semaglutide listed as shortage | 503A + 503B (bulks) permitted | Pen rationing begins |
| 2023 | Shortage deepens | Telehealth compounded boom | Patients switch to compounded en masse |
| Oct 2024 | Tirzepatide resolved (Lilly) | 503B grace window opens | Compounded tirz wind-down begins |
| Feb 21 2025 | Semaglutide removed from shortage list | 503A grace through Apr 22; 503B through May 22 | Brand supply normalizes |
| May 22 2025 | Mass 503B compounding ends | 503A patient-specific only | Some telehealth providers pivot |
| Apr 30 2026 | FDA proposes 503B Bulks List exclusion | Public comment open through Jun 29 | Compounded path further at risk |
| May 20 2026 | No shortage | 503A legal, scrutinized | Brand widely stocked |
Sources: FDA drug shortage statements, FDCA Section 503A/503B guidance. Verified May 2026.
What ‘Resolved’ Means in FDA Terms (and What It Doesn’t)
When the FDA removes a drug from its shortage list, the legal consequence is specific: compounding pharmacies lose the safe harbor that allowed them to mass-produce copies of the branded product. Under FDCA Section 503A and 503B, compounders can produce a drug that is “essentially a copy” of a commercially available product only when that product is in shortage. Once the shortage ends, that allowance ends — with a grace window.
For semaglutide, the FDA gave 503A pharmacies until Apr 22 2025 and 503B outsourcing facilities until May 22 2025 to wind down mass production. After those dates, 503A pharmacies can still compound semaglutide for individual patients with patient-specific prescriptions, but cannot stockpile, mass-produce, or distribute interstate without a prescription tied to each unit.
What “resolved” does not mean: it doesn’t mean every pharmacy on every street has every dose in stock every day. It means Novo Nordisk’s national supply matches projected national demand and that pharmacies can reliably reorder.
[provider=”ro”]
Where Local Stock Gaps Still Happen
Three patterns persist in May 2026:
- 2mg Ozempic pen. This is the highest titration dose; demand is concentrated and inventory turns faster. CVS and Walgreens stores in dense metros report 3-7 day gaps between shipments. Independent pharmacies sometimes hold inventory longer because they don’t see the same volume.
- High-demand zip codes. Manhattan, West LA, South Florida, and DC consistently show tighter inventory than suburban or rural areas. The pattern is patient density, not supply.
- End-of-quarter wholesaler lulls. Some retail chains see brief tightness in the last 10 days of each calendar quarter as wholesalers rebalance — a normal channel pattern, not a shortage.
Pharmacy-Hopping Playbook If Your Usual Store Is Out
If your CVS or Walgreens says they’re out today:
- Call before driving. Most chain pharmacies will check real-time inventory by phone.
- Try independent pharmacies. They often have stock the chains don’t, particularly in suburban areas.
- Ask your prescriber to transfer the script. Most pharmacies can pull a transfer in 15-30 minutes if both sides cooperate.
- Try a different dose temporarily. If you’re on 2mg and only 1mg is available, your prescriber may approve a short bridge — but never adjust dose on your own.
- Mail-order. Express Scripts, CVS Caremark mail, and Optum Rx home delivery often have stock when brick-and-mortar doesn’t.
What Happened to Compounded Semaglutide Post-Delisting
Compounded semaglutide didn’t disappear in 2025 — it narrowed and shifted upmarket. Several major compounding labs (ProRx and BPI Labs, among others) ceased GLP-1 production in early 2026 as legal exposure grew. Telehealth providers that previously relied on those labs scrambled to onboard new 503A partners or pivot to brand-name distribution.
[provider=”mochi-health”]
Three patterns dominate the surviving compounded market in May 2026:
- 503A telehealth providers (Mochi Health, Henry Meds, Remedy Meds) continue compounded semaglutide and tirzepatide under patient-specific prescriptions. See our Mochi Health review and Remedy Meds review.
- Sequence/WeightWatchers Clinic exited compounded GLP-1 in May 2025 and is now brand-only.
- Eli Lilly’s April 2025 lawsuit against Henry Meds over compounded tirzepatide marketing remains active and is reshaping how compounded providers describe their products.
[provider=”remedy-meds”]
For the full regulatory breakdown of what changed and why, see our compounded vs branded semaglutide guide.
April 30 2026 FDA Proposal: 503B Bulks List Exclusion
On April 30 2026, the FDA published a proposed rule that would exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — the list of bulk active pharmaceutical ingredients that outsourcing facilities are permitted to compound from. Public comments are open through June 29 2026.
If finalized, the proposal would not directly ban 503A patient-specific compounding (which operates under a different legal framework), but it would close one of the remaining pathways for larger-scale compounded GLP-1 production and would signal continued FDA tightening. Industry observers expect the rule to be finalized in late 2026.
Patients currently on compounded GLP-1s should expect their telehealth providers to message about transition options if the rule is finalized.
If You Were on Compounded During the Shortage: 3 Transition Options
- Stay on compounded via a 503A telehealth provider. Mochi Health (~$178/mo), Remedy Meds ($189-$299/mo), or Henry Meds ($197-$397/mo). Legal in 2026 but under active FDA scrutiny.
- Transition to brand-name via manufacturer self-pay. NovoCare Wegovy at $199 intro / $349 ongoing, or LillyDirect Zepbound vials at $299-$449/mo. See our GLP-1 without insurance guide for the full cash-pay matrix.
- Use insurance + savings card. Wegovy and Zepbound savings cards drop copays to ~$25/mo with commercial coverage. See our Wegovy vs Zepbound cost guide.
Brand-Name Ozempic 2026 Cash Pricing
Ozempic is on-label only for type 2 diabetes — prescribers will route obesity patients to Wegovy (same active ingredient, higher dose). For T2D patients without insurance:
- NovoCare self-pay: $349/mo most doses; $199/mo intro for the first 2 fills.
- Retail cash: $800-$1,100/mo at CVS, Walgreens, Walmart, Costco.
- GoodRx: Typically $850-$950/mo — rarely beats NovoCare.
- Medicare Part D: Covered for T2D under most plans (Ozempic is not covered for obesity-only).
How This Differs from the Wegovy and Mounjaro Stories
Wegovy (semaglutide for obesity): Same active ingredient as Ozempic, same Novo manufacturing footprint. Wegovy supply stabilized alongside Ozempic in 2025. Localized 1.7mg and 2.4mg gaps still occur but are pharmacy-level, not national.
Mounjaro (tirzepatide for T2D): Eli Lilly product. Tirzepatide was removed from the shortage list before semaglutide. Mounjaro supply is currently strong; LillyDirect vial pricing of $299-$449/mo applies (same as Zepbound). See our Mounjaro product page.
Zepbound (tirzepatide for obesity): Lilly’s obesity indication. Lilly cut LillyDirect vial pricing Feb 23 2026. Read the Wegovy vs Zepbound cost comparison for full pricing.
What to Do If Your Pharmacy Says They’re Out Today
Practical 24-hour playbook:
- Call 3-5 nearby pharmacies (chain + independent) before driving.
- Check NovoCare’s pharmacy locator for verified-stocked locations.
- Ask your prescriber for an electronic transfer to a pharmacy that has stock.
- If no stock anywhere in your metro for 5+ days, ask your prescriber about a temporary dose adjustment or a switch to Wegovy (semaglutide, different dose).
- For longer-term reliability, consider switching to mail-order or to a telehealth provider that handles pharmacy fulfillment — see our best GLP-1 telehealth 2026 guide.
For a national overview of weight-loss provider options, visit our weight-loss provider comparison hub.
Frequently Asked Questions
Is Ozempic still in shortage in 2026?
No. The FDA removed semaglutide (the active ingredient in Ozempic) from its drug shortage list on February 21, 2025, and that status holds in May 2026. Brand-name Ozempic pens are stocked at most US retail pharmacies. Localized stock gaps still occur, particularly for the 2mg pen in dense metropolitan areas, but there is no national shortage.
When did the Ozempic shortage end?
The FDA officially removed semaglutide from its drug shortage list on February 21, 2025. The agency provided a grace window for compounders to wind down: 503A patient-specific compounding through April 22, 2025, and 503B outsourcing facility compounding through May 22, 2025. After May 22, 2025, mass compounded semaglutide production ended.
Why is the 2mg Ozempic pen still hard to find?
The 2mg pen is the highest titration dose and turns over faster at pharmacies in high-demand metro areas. CVS and Walgreens locations in Manhattan, LA, Miami, and DC often see 3-7 day gaps between shipments. This is pharmacy-level inventory variance, not a national shortage. Independent pharmacies frequently have stock when chains don’t.
Can I still get compounded semaglutide in 2026?
Yes, through 503A patient-specific compounding under a prescription tied to you individually. Mass 503B compounding from the bulks list ended May 22, 2025. Telehealth providers like Mochi Health, Henry Meds, and Remedy Meds continue compounded semaglutide. The FDA’s April 30, 2026 proposal to exclude semaglutide from the 503B Bulks List, with comments open through June 29, 2026, could further narrow the legal landscape.
How much does Ozempic cost without insurance in 2026?
NovoCare self-pay is $349/month for most doses, with $199/month intro pricing for the first two fills. Retail cash at CVS, Walgreens, and Walmart runs $800-$1,100/month. GoodRx typically shaves retail to $850-$950 — rarely beating NovoCare. Medicare Part D covers Ozempic for type 2 diabetes (not obesity). NovoCare self-pay is unavailable to Medicare beneficiaries.
What should I do if my pharmacy is out of Ozempic?
Call 3-5 nearby pharmacies (chains and independents) to check real-time inventory before driving. Ask your prescriber to electronically transfer the script to a pharmacy with stock. Try mail-order through Express Scripts, CVS Caremark, or Optum Rx. If no stock is available for 5+ days, ask your prescriber about a temporary dose adjustment — never self-adjust dose.
Will the Ozempic shortage come back?
It’s unlikely at the national level. Novo Nordisk scaled US manufacturing materially through 2024-2025, and current capacity matches projected demand. Localized stock gaps will continue at the pharmacy level — that’s normal channel variance, not a shortage. The bigger 2026 supply question is whether FDA tightening of compounding narrows the secondary supply lane that absorbed demand during 2022-2024.
Is Mounjaro also in shortage?
No. Tirzepatide (the active ingredient in Mounjaro and Zepbound) was removed from the FDA shortage list before semaglutide. Mounjaro pens and LillyDirect vials are widely available in May 2026. LillyDirect vial pricing is $299/month for 2.5mg, $399 for 5mg, and $449 for 7.5-15mg with a 45-day refill rule.
Is Wegovy in shortage in 2026?
No. Wegovy uses the same active ingredient (semaglutide 2.4mg) and the same Novo Nordisk manufacturing footprint as Ozempic, and stabilized at the same time. Some localized gaps for 1.7mg and 2.4mg pens occur in high-demand metro areas, but there’s no national shortage. NovoCare self-pay is $199 intro / $349 ongoing per month.
Can I switch from Ozempic to Wegovy if my pharmacy is out?
Only if your prescriber writes a new prescription and your diagnosis supports it. Ozempic is on-label for type 2 diabetes; Wegovy is on-label for obesity at higher doses. Same active ingredient, different titration. Insurance coverage and savings card eligibility differ between the two products, so confirm pricing before switching. Never substitute on your own.
Sources
- FDA — Policies for Compounders as GLP-1 Supply Stabilizes (verified May 2026)
- Burr — FDA Removes Semaglutide from Drug Shortage List (Feb 21 2025)
- NovoCare Ozempic patient information (verified May 2026)
- Drug Topics — GLP-1 No Longer on FDA Shortage List
- Federal Register — Apr 30 2026 503B Bulks List proposed rule (comments open through Jun 29 2026)
Medical disclaimer: Information here is educational only. GLP-1 medications can cause serious side effects including pancreatitis, gallbladder disease, and thyroid C-cell tumors (boxed warning). Consult a licensed clinician before starting, switching, or stopping any prescription weight-loss medication.
Health Disclaimer: BestMedsHub is not a healthcare provider, telehealth service, pharmacy, or medical organization. We do not prescribe medication, diagnose conditions, render medical opinions, or facilitate clinical consultations. All content is for general informational and comparison purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified physician, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any treatment, medication, supplement, or health program. Never disregard professional medical advice or delay seeking it because of anything you have read on this site. If you think you may have a medical emergency, call your local emergency number immediately.
FDA & Prescription Medication Disclaimer: Prescription medications referenced on this page are available only through a licensed healthcare provider after a clinical evaluation, and may not be appropriate or safe for everyone. Any statements regarding dietary supplements, wellness products, or off-label uses have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary and are not guaranteed. Always read the medication guide and consult your prescriber and pharmacist about side effects, contraindications, and drug interactions.
